mardi 4 juin 2019

Onco Actu du 4 juin 2019 - spécial ASCO


5.5.1 ASCO (GÉNÉRAL)



At cancer conference, debate over speedy drug approvals in the spotlight [Biopharma Dive]










5.5.10 ASCO (HÉMATO)



ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win [Fierce Pharma]











IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL) [Janssen]











J&J, Genmab strengthen case for Darzalex in frontline multiple myeloma with fresh slate of PhIII data [EndPoints]











Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting [Seattle Genetics]











5.5.13 ASCO (DIVERS)



Without older subjects, cancer drugs trials rely on atypical patients [Reuters]










Fitbits prescribed to cancer patients could boost survival rates, research suggests [The Telegraph]











A Plea For A Focus On The Humanity Of Cancer Care: Are We Missing An Opportunity When It Comes To Artificial Intelligence? [Dr. Len]










5.5.13.3 ASCO (DIVERS-CHIRURGIE)



Colorectal Cancer Patients With Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery [ASCO]










5.5.14 ASCO (VESSIE)



Yale Cancer Center researchers show novel drug increased survival for bladder cancer patients [Yale Cancer Center]











ASCO: Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers [Fierce Biotech]











Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients With Advanced Urothelial Cancer [ASCO]











#ASCO19: Clay Siegall is ready to take a big leap forward as Seattle Genetics’ next top drug prospect steps onto center stage at ASCO [EndPoints]











Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer [Seattle Genetics]











Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study [Reuters]











5.5.15 ASCO (BIOPSIES LIQUIDES)



Grail's Newest Early Cancer Detection Data Lays Path for Return of Results Next Year [Genome Web]











5.5.16.1 ASCO (MÉDECINE DE PRÉCISION-TRK/RET)



Blueprint keeps pressure on Lilly with RET-targeted cancer therapy [Biopharma Dive]











New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019 [Bayer]











Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019 [Blueprint Medicines]











Larotrectinib, first targeted therapy for childhood solid tumours, shown to be effective [Gustave Roussy]










5.5.16.3 ASCO (MÉDECINE DE PRÉCISION-KRAS)



ASCO: Amgen's closely watched KRAS drug, first to clinic, shrinks NSCLC, curbs colorectal tumors [Fierce Biotech]










Early cancer drug data give Amgen hope it has 'cracked KRAS code' [Biopharma Dive]











#ASCO19: Amgen grows more confident in KRAS G12C drug with a positive snapshot for lung cancer — shares spike [EndPoints]











Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019 [Amgen]











Amgen drug shows high response rate in small lung and colon cancer trial [Reuters]











5.5.2 ASCO (SEIN)



Hortobagyi honored by ASCO for his work against breast cancer [MD Anderson Cancer Center]











5.5.4 ASCO (IMMUNOTHÉRAPIES)



New head and neck cancer drug could help patients live longer [The Guardian]











ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer [Institute of Cancer Research]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



ASCO: Gilead touts CAR-T franchise with Yescarta analyses, early data on pipeline drug [Fierce Pharma]










5.5.6 ASCO (PEAU-MÉLANOME)



ASCO: Complete response rate in Nektar melanoma trial hits 34% [Fierce Biotech]











Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) [BMS]











5.5.7 ASCO (GYNÉCO)



Lynparza achieved a 72% objective response rate in patients with relapsed, germline BRCA-mutated advanced ovarian cancer [AstraZeneca]











Over 60 Percent of Gynecologic Oncologists Say They Have Experienced Sexual Harassment [ASCO]











5.5.8 ASCO (POUMON)



Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials [Novartis]











Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib) [Takeda]











Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer [ASCO]











5.5.9 ASCO (AUTRES ORGANES)



Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting [Epizyme]











ASCO: With FDA review nearing, Epizyme shares updated sarcoma data [Fierce Biotech]











Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019 [BMS]